Phase I Trial of OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] Treatment in Patients With Advanced and/or Metastatic Pancreatic Adenocarcinoma

Next Previous
Trial Profile

Phase I Trial of OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] Treatment in Patients With Advanced and/or Metastatic Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
    • 20 Jan 2018 Status changed from recruiting to active, no longer recruiting according to results presented at the 2018 Gastrointestinal Cancers Symposium.
    • 17 Dec 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top